Valley Brook Capital Group Inc. Decreases Stock Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Valley Brook Capital Group Inc. lessened its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 6.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 700 shares of the company’s stock after selling 50 shares during the quarter. Valley Brook Capital Group Inc.’s holdings in IDEXX Laboratories were worth $389,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the stock. Connecticut Wealth Management LLC increased its position in IDEXX Laboratories by 3.9% during the fourth quarter. Connecticut Wealth Management LLC now owns 620 shares of the company’s stock valued at $344,000 after acquiring an additional 23 shares during the last quarter. National Bank of Canada FI increased its position in shares of IDEXX Laboratories by 119.0% during the 4th quarter. National Bank of Canada FI now owns 66,167 shares of the company’s stock valued at $36,239,000 after purchasing an additional 35,958 shares during the last quarter. FourThought Financial Partners LLC bought a new position in shares of IDEXX Laboratories in the 4th quarter worth approximately $201,000. TCG Advisory Services LLC purchased a new position in shares of IDEXX Laboratories in the fourth quarter worth approximately $24,155,000. Finally, Sapient Capital LLC bought a new stake in IDEXX Laboratories during the fourth quarter valued at approximately $18,842,000. 87.84% of the stock is currently owned by institutional investors.

Insider Buying and Selling at IDEXX Laboratories

In other IDEXX Laboratories news, CFO Brian P. Mckeon sold 23,326 shares of IDEXX Laboratories stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $570.01, for a total value of $13,296,053.26. Following the sale, the chief financial officer now directly owns 29,718 shares in the company, valued at approximately $16,939,557.18. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other IDEXX Laboratories news, CFO Brian P. Mckeon sold 23,326 shares of IDEXX Laboratories stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $570.01, for a total value of $13,296,053.26. Following the sale, the chief financial officer now directly owns 29,718 shares in the company, valued at approximately $16,939,557.18. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP George Fennell sold 8,198 shares of the business’s stock in a transaction dated Thursday, February 8th. The stock was sold at an average price of $573.87, for a total transaction of $4,704,586.26. Following the completion of the sale, the senior vice president now owns 6,712 shares in the company, valued at $3,851,815.44. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 43,524 shares of company stock worth $24,871,960. Insiders own 2.11% of the company’s stock.

IDEXX Laboratories Price Performance

Shares of IDXX stock traded up $4.78 on Friday, hitting $480.60. 547,954 shares of the stock traded hands, compared to its average volume of 509,434. The firm has a market cap of $39.69 billion, a price-to-earnings ratio of 46.52, a PEG ratio of 3.78 and a beta of 1.27. IDEXX Laboratories, Inc. has a 52 week low of $372.50 and a 52 week high of $583.39. The firm has a 50 day simple moving average of $523.29 and a two-hundred day simple moving average of $513.58. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.57 and a quick ratio of 1.17.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Monday, February 5th. The company reported $2.32 EPS for the quarter, beating the consensus estimate of $2.12 by $0.20. The firm had revenue of $901.60 million for the quarter, compared to the consensus estimate of $891.88 million. IDEXX Laboratories had a net margin of 23.26% and a return on equity of 63.66%. The company’s revenue was up 8.8% on a year-over-year basis. During the same period last year, the firm earned $2.05 EPS. As a group, equities research analysts predict that IDEXX Laboratories, Inc. will post 11.05 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have weighed in on IDXX shares. The Goldman Sachs Group increased their price target on shares of IDEXX Laboratories from $500.00 to $650.00 and gave the stock a “buy” rating in a research report on Wednesday, January 17th. JPMorgan Chase & Co. increased their price target on shares of IDEXX Laboratories from $600.00 to $630.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 6th. Barclays decreased their price target on shares of IDEXX Laboratories from $655.00 to $570.00 and set an “overweight” rating on the stock in a research report on Thursday. Piper Sandler downgraded shares of IDEXX Laboratories from an “overweight” rating to a “neutral” rating and set a $525.00 price target on the stock. in a research report on Tuesday, January 30th. Finally, StockNews.com downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Thursday. Four investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, IDEXX Laboratories has an average rating of “Moderate Buy” and an average price target of $580.88.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.